• Cyclo (-RGDfC): High-Affinity αvβ3 Integrin Binding Pepti...

  2026-02-05

  Cyclo (-RGDfC) is a cyclic RGD peptide with high specificity for the integrin αvβ3 receptor, crucial for tumor targeting and angiogenesis research. Its robust DMSO solubility and validated purity make it a reliable tool for integrin-mediated cell adhesion studies. This article provides mechanistic context, benchmarks, and practical integration guidance for Cyclo (-RGDfC) in advanced biomedical workflows.

• Pioglitazone: PPARγ Agonist Workflows for Metabolic and I...

  2026-02-04

  Pioglitazone empowers researchers investigating PPARγ signaling in metabolic, inflammatory, and neurodegenerative models with precise control and reproducible outcomes. Explore advanced experimental workflows, troubleshooting strategies, and the unique translational leverage provided by APExBIO's high-purity Pioglitazone.

• Cyclo (-RGDfC): Transforming Integrin αvβ3 Targeting in T...

  2026-02-04

  Cyclo (-RGDfC), a cyclic RGD peptide from APExBIO, exemplifies the next generation of integrin αvβ3 receptor targeting for tumor and angiogenesis research. This thought-leadership article synthesizes mechanistic insights, experimental best practices, and strategic guidance for translational researchers, integrating landmark findings from canine osteosarcoma studies and real-world laboratory workflows. We expand the dialogue beyond standard product pages, envisioning a future where precise integrin targeting accelerates discovery and therapeutic innovation.

• Gastrin I (human): Precision Modulation of Gastric Acid S...

  2026-02-03

  Explore the advanced scientific utility of Gastrin I (human) as a gastric acid secretion regulator and CCK2 receptor agonist for cutting-edge gastrointestinal physiology studies. This article uniquely delves into mechanistic modulation, innovative in vitro modeling, and translational applications in GI disorder research.

• Unlocking the Translational Potential of Neuropeptide Y Y...

  2026-02-03

  BIIE 0246, a selective neuropeptide Y Y2 receptor antagonist, is revolutionizing translational neuroscience and cardiometabolic research. This thought-leadership article synthesizes mechanistic insights into NPY Y2R signaling, highlights strategic experimental frameworks, and explores the translational promise of Y2R antagonism in feeding behavior, anxiety, and the adipose-neural axis. Drawing from recent breakthroughs—including Fan et al.'s elucidation of the adipose-neural axis in cardiac arrhythmias—this guide empowers researchers to advance the science with BIIE 0246 (SKU B6836), available from APExBIO.

• BIBP 3226 trifluoroacetate: Precision NPY Y1/NPFF Recepto...

  2026-02-02

  BIBP 3226 trifluoroacetate is a highly selective non-peptide antagonist targeting NPY Y1 and NPFF receptors, enabling precise dissection of neuropeptide signaling pathways in anxiety, analgesia, and cardiovascular studies. Its high binding affinity and well-defined pharmacological profile make it a reference compound for mechanistic studies of the NPY/NPFF system. Researchers leverage BIBP 3226 trifluoroacetate to interrogate adipose-neural axis function and cAMP signaling inhibition in translational models.

• Pioglitazone: PPARγ Agonist Workflows for Metabolic & Inf...

  2026-02-02

  Pioglitazone, a potent PPARγ agonist from APExBIO, enables precision modulation of immune-metabolic pathways in disease models from diabetes to neuroinflammation. This guide delivers actionable protocols, troubleshooting tactics, and strategic context for maximizing reproducibility and impact in PPAR signaling research.

• 2-Deoxy-D-glucose: A Versatile Glycolysis Inhibitor for M...

  2026-02-01

  2-Deoxy-D-glucose (2-DG) is a benchmark glycolysis inhibitor that empowers researchers to dissect cancer metabolism, immune cell function, and viral replication with precision. With robust performance in KIT-positive gastrointestinal stromal tumor and non-small cell lung cancer models, as well as antiviral workflows, 2-DG from APExBIO ensures reproducible, high-impact results. Discover advanced protocols, troubleshooting insights, and emerging applications in metabolic research.

• Gastrin I (human): Redefining CCK2 Receptor Agonist Research

  2026-01-31

  Discover how Gastrin I (human) advances gastric acid secretion pathway research and unlocks new frontiers in gastrointestinal physiology studies. This article offers a unique systems-level perspective, integrating stem cell-derived organoid models for translational insight.

• 2'3'-cGAMP (Sodium Salt): Unraveling the cGAS-STING Pathw...

  2026-01-30

  Explore the advanced scientific landscape of 2'3'-cGAMP (sodium salt) as a STING agonist in the context of cellular senescence, SASP modulation, and next-generation cancer immunotherapy. Delve into unique mechanistic insights and translational strategies for immunology research.

• 2-Deoxy-D-glucose (2-DG): Solving Real-World Assay Challe...

  2026-01-30

  This article delivers scenario-driven, evidence-based guidance for biomedical researchers and lab technicians using 2-Deoxy-D-glucose (2-DG, SKU B1027) as a glycolysis inhibitor in cell viability, proliferation, and cytotoxicity assays. Drawing on recent literature and explicit product parameters, it demonstrates how APExBIO’s 2-DG supports reproducible, quantitative results across cancer, immunometabolic, and viral studies.

• Cyclo (-RGDfC): Precision αvβ3 Integrin Targeting Peptide...

  2026-01-29

  Cyclo (-RGDfC), a cyclic RGD peptide, offers high-affinity and specificity for the αvβ3 integrin receptor. This integrin αvβ3 receptor targeting peptide is a benchmark tool for cancer research and angiogenesis studies. Its validated performance, solubility, and workflow integration make it a preferred choice for high-throughput and mechanistic investigations.

• Parathyroid hormone (1-34) (human): Redefining Kidney Dis...

  2026-01-29

  Explore how Parathyroid hormone (1-34) (human) is transforming calcium homeostasis and bone metabolism research. This article uniquely examines its mechanistic role as a parathyroid hormone 1 receptor agonist within next-generation kidney assembloid models and osteoporosis studies.

• 2-Deoxy-D-glucose: Advanced Modulation of Tumor and Immun...

  2026-01-28

  Explore the multifaceted role of 2-Deoxy-D-glucose (2-DG), a potent glycolysis inhibitor, in cancer metabolism, immune reprogramming, and antiviral research. This article uniquely integrates metabolic checkpoint science with translational applications, offering a deeper analysis of 2-DG's impact on tumor microenvironment and immunometabolic pathways.

• Pioglitazone: PPARγ Agonist for Metabolic & Inflammatory ...

  2026-01-28

  Pioglitazone is a selective PPARγ agonist widely used for type 2 diabetes mellitus research and studies of inflammatory process modulation. Recent evidence supports its utility in regulating macrophage polarization and oxidative stress reduction. APExBIO's Pioglitazone (B2117) enables reproducible workflows for insulin resistance mechanism studies.

16030 records 2/1069 page Previous Next 12345 下5页 Last page